Disease-specific outcomes after chimeric antigen receptor T-cell therapy - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue European Journal of Cancer Année : 2022

Disease-specific outcomes after chimeric antigen receptor T-cell therapy

Résumé

We compared outcomes of patients with B-cell malignancies treated in clinical trials with the same CD19 chimeric antigen receptor (CAR) T-cells across different indications, including B-cell acute lymphoblastic leukaemia (B-ALL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL) and follicular lymphoma (FL). We found that for a given CAR T-cell, efficacy and toxicity varied depending on the disease. Overall, we found a low rate of primary resistance in FL, MCL and B-ALL compared with DLBCL. Acute toxicities (cytokine release syndrome and ICANS) appeared to be significantly less severe in FL compared with more aggressive diseases, such as B-ALL, DLBCL and MCL. These observations suggest that each B-cell malignancy harbours specific biology, which may interact differently with CAR T-cell therapy. Thus, CAR T-cells may be tailored differently depending on the type of B-cell malignancy to optimise their efficacy and safety.

Domaines

Cancer
Fichier principal
Vignette du fichier
S0959804921011801.pdf (234.67 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-03519676 , version 1 (08-01-2024)

Licence

Paternité - Pas d'utilisation commerciale

Identifiants

Citer

Jean Lemoine, Samuel Vic, Roch Houot. Disease-specific outcomes after chimeric antigen receptor T-cell therapy. European Journal of Cancer, 2022, 160, pp.235-242. ⟨10.1016/j.ejca.2021.10.022⟩. ⟨hal-03519676⟩
28 Consultations
3 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More